These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29295936)

  • 1. Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.
    Lu L; Zhu F; Zhang M; Li Y; Drennan AC; Kimpara S; Rumball I; Selzer C; Cameron H; Kellicut A; Kelm A; Wang F; Waldmann TA; Rui L
    Proc Natl Acad Sci U S A; 2018 Jan; 115(3):E498-E505. PubMed ID: 29295936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
    Lam LT; Wright G; Davis RE; Lenz G; Farinha P; Dang L; Chan JW; Rosenwald A; Gascoyne RD; Staudt LM
    Blood; 2008 Apr; 111(7):3701-13. PubMed ID: 18160665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
    Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
    Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
    Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
    J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
    Yang Y; Shaffer AL; Emre NC; Ceribelli M; Zhang M; Wright G; Xiao W; Powell J; Platig J; Kohlhammer H; Young RM; Zhao H; Yang Y; Xu W; Buggy JJ; Balasubramanian S; Mathews LA; Shinn P; Guha R; Ferrer M; Thomas C; Waldmann TA; Staudt LM
    Cancer Cell; 2012 Jun; 21(6):723-37. PubMed ID: 22698399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.
    Ding BB; Yu JJ; Yu RY; Mendez LM; Shaknovich R; Zhang Y; Cattoretti G; Ye BH
    Blood; 2008 Feb; 111(3):1515-23. PubMed ID: 17951530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation.
    Yao S; Xu F; Chen Y; Ge Y; Zhang F; Huang H; Li L; Lin D; Luo X; Xu J; Luo D; Zhu X; Liu Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):10. PubMed ID: 28069035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.
    Ok CY; Chen J; Xu-Monette ZY; Tzankov A; Manyam GC; Li L; Visco C; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Zhao X; Ponzoni M; Ferreri AJ; Bertoni F; Farnen JP; Møller MB; Piris MA; Winter JN; Medeiros LJ; Young KH
    Clin Cancer Res; 2014 Oct; 20(19):5113-23. PubMed ID: 25124685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGR1 Addiction in Diffuse Large B-cell Lymphoma.
    Kimpara S; Lu L; Hoang NM; Zhu F; Bates PD; Daenthanasanmak A; Zhang S; Yang DT; Kelm A; Liu Y; Li Y; Rosiejka A; Kondapelli A; Bebel S; Chen M; Waldmann TA; Capitini CM; Rui L
    Mol Cancer Res; 2021 Aug; 19(8):1258-1269. PubMed ID: 33980611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
    Lyu MA; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Rosenblum MG
    Biochem Pharmacol; 2010 Nov; 80(9):1335-42. PubMed ID: 20654581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB.
    Solomon LA; Batista CR; DeKoter RP
    Exp Hematol; 2017 Dec; 56():46-57.e1. PubMed ID: 28893618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma.
    Rui L; Drennan AC; Ceribelli M; Zhu F; Wright GW; Huang DW; Xiao W; Li Y; Grindle KM; Lu L; Hodson DJ; Shaffer AL; Zhao H; Xu W; Yang Y; Staudt LM
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7260-E7267. PubMed ID: 27799566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT3 targets suggest mechanisms of aggressive tumorigenesis in diffuse large B-cell lymphoma.
    Hardee J; Ouyang Z; Zhang Y; Kundaje A; Lacroute P; Snyder M
    G3 (Bethesda); 2013 Dec; 3(12):2173-85. PubMed ID: 24142927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy.
    Gupta M; Han JJ; Stenson M; Wellik L; Witzig TE
    Leukemia; 2012 Jun; 26(6):1356-64. PubMed ID: 22116549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
    Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
    Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway.
    Li XD; Li XM; Gu JW; Sun XC
    Eur Rev Med Pharmacol Sci; 2017 Nov; 21(22):5153-5159. PubMed ID: 29228427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
    Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma.
    Scuto A; Kujawski M; Kowolik C; Krymskaya L; Wang L; Weiss LM; Digiusto D; Yu H; Forman S; Jove R
    Cancer Res; 2011 May; 71(9):3182-8. PubMed ID: 21521803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.
    Han SS; Yun H; Son DJ; Tompkins VS; Peng L; Chung ST; Kim JS; Park ES; Janz S
    Mol Cancer; 2010 Apr; 9():97. PubMed ID: 20433747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.